Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes

Pharmacology

Volumn 59, Issue 6, 1999, Pages 298-309

  Olesen, Ole V ^a   Linnet, Kristian ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Citalopram; Cytochrome P450; Metabolism; Stereoselectivity

Indexed keywords

CITALOPRAM; COMPLEMENTARY DNA; CYTOCHROME P450; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DEMETHYLATION; DRUG METABOLISM; ENANTIOMER; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; STEREOCHEMISTRY;

EID: 0032706936     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028333     Document Type: Article

References (31)

1. Milne RJ, Goa KL: Citalopram: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450-477.
2. Hyttel J: Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9:19-26.
3. Hyttel J, Bogeso KP, Perregaard J, Sanchez C: The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992;88:157-160.
4. Dalgaard L, Jensen KG, Andersen JB, Jensen B, Larsen CS: Metabolism of citalopram in man. ISSX Proc (ISSN 1061-3439), 1995.
5. Oyehaug E, Ostensen ET, Salvesen B: High-performance liquid Chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr 1984;308:199-208.
6. Baumann P, Larsen F: The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-295.
7. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y: Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997;280:927-933.
8. Rochat B, Amey M, Gillet M, Meyer UA, Baumann P: Identification of three cytochrome P450 isozymes involves in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997;7:1-10.
9. Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P: Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 1998;56:15-23.
10. Linnet K, Olesen OV: Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997;25:1379-1382.
11. Fuhr U, Doehmer J, Battula N, Wolfel C, Kudla C, Keita Y, Staib AH: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol 1992; 43:225-235.
12. Olesen OV, Linnet K: Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 1997;55:235-243.
13. Leemann T, Transon C, Dayer P: Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1993;52:29-34.
14. Hall SD, Guengerich FP, Branch RAm, Wilkinson GR: Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther 1987;240:216-222.
15. Dahl ML, Nordin C, Bertilsson L: Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther Drug Monit 1991;13:189-194.
16. Kim RB, O'Shea D: Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYPE2E1 genetic polymorphisms. Clin Pharmacol Ther 1995;67:645-655.
17. Olesen OV, Linnet K: Simplified high-performance liquid chromatographic method for the determination of citalopram and desmethylcitalopram in serum without interference from commonly used psychotropic drugs and their metabolites. J Chromatogr [B] 1996;675:83-88.
18. Motulsky H: Intuitive Biostatistics. London, Oxford University Press, 1995, pp 279-282.
19. m in enzyme reactions. Science 1952;116:329-331.
20. Rochat B, Amey M, Baumann P: Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 1995;17:273-279.
21. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F: Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 1997;9:686-692.
22. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K: Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78.
23. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RW, Beck DJ, Bertino JS Jr: Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998;64:257-268.
24. Olesen OV, Linnet K: Fluvoxamine-clozapine drug interaction: Inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 1999;in press.
25. Sindrup SH, Brosen K, Hansen MG, Aaes-Jorgensen T, Overo KF, Gram LF: Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15: 11-17.
26. Gram LF, Hansen MG, Sindrup SH, Brosen K, Poulsen JH, Aaes-Jorgensen T, Overo KF: Citalopram: Interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993;15: 18-24.
27. Øyehaug E, Eide E, Salvesen B: Effect of phenothiazines on citalopram steady-state kinetics in psychiatric patients. Nord Pharm Acta 1984;46: 37-46.
28. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI: Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol 1998;18: 256.
29. Leinonen E, Lepola U, Koponen H: Substituting carbamazepine with oxcarbazepine increases citalopram levels: A report on two cases. Pharmacopsychiatry 1996;29:156-158.
30. Priskorn M, Larsen F, Segonzac A, Moulin M: Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects. Eur J Clin Pharmacol 1997;52:241-242.
31. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P: Non-response to citalopram in depressive patients: Pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology(Berl) 1996;128:421-425.